龙血竭辅助治疗糖尿病足溃疡的疗效与安全性:随机对照试验的Meta分析
结果显示联合治疗显著改善总体愈合反应(RR=0.28,95%CI 0.20-0.39,P<0.00001)、缩短创面愈合时间(MD=-11.66,95%CI -21.62至-1.69,P=0.02)并降低血清C反应蛋白水平(MD=-1.99,95%CI -2.99至-0.99,P<0.0001),未报告严重不良事件。
要点
- 龙血竭联合常规治疗可显著改善糖尿病足溃疡的总体愈合反应。
- 联合治疗可缩短创面愈合时间并降低血清C反应蛋白水平。
- 未报告严重不良事件,但样本量有限且可能存在发表偏倚。
核心结论
- 龙血竭可能是糖尿病足溃疡有效且安全的辅助治疗,可能促进创面愈合和减轻全身炎症。
- 因纳入研究样本量有限且可能存在发表偏倚,结论需谨慎解读,尚需大规模严格设计的RCT证实。
研究设计与样本
- 二分类结局用风险比(RR)表示,连续结局用均数差(MD)表示,均附95%置信区间(CI)。
主要发现
- 龙血竭辅助治疗显著改善总体愈合反应(RR=0.28;95%CI 0.20-0.39;P<0.00001)。
- 龙血竭辅助治疗缩短创面愈合时间(MD=-11.66;95%CI -21.62至-1.69;P=0.02)。
- 龙血竭辅助治疗降低血清C反应蛋白水平(MD=-1.99;95%CI -2.99至-0.99;P<0.0001)。
- 未报告严重不良事件。
临床怎么用
- 在常规治疗基础上可考虑联合龙血竭辅助治疗糖尿病足溃疡,以促进愈合和减轻炎症。
- 临床决策需结合患者具体情况,并注意现有证据的局限性和发表偏倚风险。
局限性
- 纳入研究样本量有限。
- 纳入研究可能存在发表偏倚。
- 尚需大规模、严格设计的随机对照试验确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resina Draconis, a traditional Chinese herbal medicine with wound-healing properties, has been increasingly used as an adjunctive treatment for diabetic foot ulcers (DFUs). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Resina Draconis in the treatment of DFUs. METHODS: Five electronic databases were systematically searched for randomized controlled trials (RCTs) published up to December 2025. Eligible studies compared Resina Draconis combined with conventional therapy versus conventional therapy alone in patients with DFUs. Dichotomous outcomes were expressed as risk ratios (RRs), and continuous outcomes as mean differences (MDs), both with 95% confidence intervals (CIs). RESULTS: Fourteen RCTs involving 1,011 participants were included. The meta-analysis showed that adjunctive treatment with Resina Draconis significantly improved the overall healing response (RR = 0.28; 95% CI, 0.20-0.39; P < 0.00001), shortened wound-healing time (MD = -11.66; 95% CI, -21.62 to -1.69; P = 0.02), and reduced serum C-reactive protein levels (MD = -1.99; 95% CI, -2.99 to -0.99; P < 0.0001). No serious adverse events were reported. CONCLUSIONS: Resina Draconis may be an effective and safe adjunctive therapy for DFUs, potentially enhancing wound healing and reducing systemic inflammation. However, the findings should be interpreted cautiously because of the limited sample sizes and potential publication bias of the included studies. Further large-scale, rigorously designed RCTs are needed to confirm these results. SYSTEMATIC REVIEW REGISTRATION: Identifier CRD42020189060.
引用
- Zhou S, Guan Y, Yu Q, et al. Efficacy and safety of resina draconis as an adjuvant therapy for diabetic foot ulcer: a meta-analysis of randomized controlled trials. Front Pharmacol. 2026. PMID: 42558831. doi:10.3389/fphar.2026.1823436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。